Home›Screener›VERV›Profile
C
62/100

Verve Therapeutics

VERVCardiovascular
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Verve Therapeutics (VERV) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 1[1].

No Form 4 insider filings for VERV were recorded at the SEC in the past 30 days[3].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. SEC EDGAR (2026-04-11) ↗
🔬
Clinical Trials
3
NCT06112327Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia, Hypercholesterolemia
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06451770Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials5
Sector Peers (Cardiovascular)
CUBLionheart Holdings Class A
B
HSCSHeartSciences Inc.
B
AMRNAmarin Corporation
D
BEATHeartbeam, Inc.
D
CYTKCytokinetics Inc
D
Data Provenance
clinical trial3 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR